Treatment of lymphangioleiomyomatosis by ovariectomy, interferon alpha 2b and tamoxifen--a case report.
The gender-specific prevalence of lymphangioleiomyomatosis (LAM) in premenopausal women suggests a hormonal etiology. Despite the antiestrogenic treatment (ovariectomy, tamoxifen) this disease is often refractory to therapy and almost inevitably leads to the patient's death. We describe a case where the antiproliferative effect of systemically applied interferon alpha 2b was successfully employed in addition to ovariectomy and the patient reached complete remission.
Klein
M
M
Department of Gynecology and Obstetrics, Hanusch-Krankenhaus, Vienna, Austria.
Krieger
O
O
Ruckser
R
R
Rosen
A
A
Waldner
R
R
Preis
P
P
Beck
A
A
D000328:Adult; D002916:Chylothorax / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008203:Lymphangiomyoma / Q000628:therapy*; D008479:Mediastinal Neoplasms / Q000628:therapy*; D010052:Ovariectomy; D010386:Pelvic Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins; D012186:Retroperitoneal Neoplasms / Q000628:therapy*; D013629:Tamoxifen / Q000008:administration & dosage*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013629:Tamoxifen